This project aims to combine computational tools applied to drug repositioning and in vitro studies to identify drugs with activity against SARS-CoV-2. Initially, the SARS-CoV-2 molecular targets that offer the greatest potential to be affected by the molecules/drugs of interest and trigger antiviral effects will be selected. Part of these targets has already been selected, considering the relevance proven in previous in vitro studies. Innovative molecular targets for SARS-CoV-2 will be determined from integrative transcriptome analysis. After selecting the targets of interest, the interaction and affinity between each target with the drugs in clinical use deposited in our database will be investigated, as well as promising molecules of natural origin already commercialized. The cytotoxicity of drugs/molecules and their combinations will be investigated in vitro in different cell types. The drugs/molecules and their combinations with greater potential for in silico interaction and less cytotoxicity in vitro will be investigated in relation to their activity against SARS-CoV-2.
